Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, but its business portfolio remains resilient, supporting growth in several segments [1]. Financial Performance - Revenue for the six months ending June 30, 2025, was RMB 1.2706 billion, a decrease of approximately 13.3% year-on-year [1]. - Profit for the same period was RMB 28.6 million, down 72.4% year-on-year [1]. Business Segments - The co-construction business saw a revenue increase of 30% year-on-year, with a four-year CAGR of 48%, driven by successful projects with major hospitals [1]. - The CRO business experienced an 18% year-on-year revenue growth, maintaining a strong position in diabetes and achieving breakthroughs in solid tumor treatments [1]. - The special inspection business revenue declined by 6%, although key product lines, such as oncology, grew by over 9% [1]. Strategic Initiatives - The company plans to deepen strategic collaborations with leading medical institutions to promote more benchmark projects in the second half of 2025 [1]. - In May 2025, the company announced the acquisition of Yuan De You Qin, a leading enterprise in the blood disease diagnostics field, and is progressing with collaborative plans [2]. - The company has identified high-potential target clients through detailed mapping of tertiary hospital customers and is focusing on key hospitals for follow-up and collaboration [2].
艾迪康控股(09860.HK)上半年期内溢利跌72.4%至2860万元